Massimo Breccia

Pubblicazioni

Titolo Pubblicato in Anno
A Multicenter Real-Life Study On Anticoagulant Treatment With Direct Oral Anticoagulants In Patients With Ph Negative Myeloproliferative Neoplasms AMERICAN JOURNAL OF HEMATOLOGY 2020
Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors CLINICAL DRUG INVESTIGATION 2020
Early Palliative Home Care versus Hospital Care for Patients with Hematologic Malignancies: A Cost-Effectiveness Study JOURNAL OF PALLIATIVE MEDICINE 2020
5. Balanced and Unbalanced Chromosomal Translocatios in Myelodysplastic Syndromes: Clinical and Prognostic Signficance. LEUKEMIA & LYMPHOMA 2020
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy LEUKEMIA 2020
Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached ECLINICALMEDICINE 2020
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index LEUKEMIA 2020
First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an ``operational cure{''} THE LANCET. HAEMATOLOGY 2020
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial LEUKEMIA 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data HEMATOLOGICAL ONCOLOGY 2020
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA) CANCER MEDICINE 2020
Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors LEUKEMIA 2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors ANNALS OF HEMATOLOGY 2020
Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism HAEMATOLOGICA 2020
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia FRONTIERS IN ONCOLOGY 2020
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. ACampus CMLstudy BLOOD CANCER JOURNAL 2020
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the ``Ph1-negative Myeloproliferative Neoplasms Latium Group{''} EUROPEAN JOURNAL OF HAEMATOLOGY 2020
Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning BRITISH JOURNAL OF HAEMATOLOGY 2020
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey LEUKEMIA 2020
How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey LEUKEMIA 2020

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma